Jazz Pharmaceuticals plc — Director's Dealing 2022

Aug 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-08-04

Reporting Person: Pearce Samantha (SVP, Head of Europe & Internat)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-04	Ordinary Shares	M	531	$109.45	Acquired	11840	Direct
2022-08-04	Ordinary Shares	S	531	$155.0	Disposed	11309	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-04	Non-Qualified Stock Option (right to buy)	$109.45	M	531	Disposed	2030-05-06	Ordinary Shares (531)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.